Member Info for researcher1

Master Investor I say good. Motley Fool and Investors Chronicle I say bad.

I've just taken a look at the fundamentals, and revenue v MCAP and the sp seems totally crazy, even with a few FCA concerns knocking about. I'm not a fan of this sector but have decided to take some shares anyway, as otherwise it is like turning down a cash gift.

I'm a buyer up to 185 (on leverage) selling after 225 - I think the rise will recommence on Monday, after analyst reports etc, but any new contract will move it higher, and fast....

I doubled my holding yesterday on the general AIM weakness. Anyone else suffering data feed issues this morning ? (IG CFD account...)

doubled down today to get a 161 average - holding for 225.

back in again today at 70p - could go a couple of pence lower but then will spring back as usual...

and AN has his sights well beyond £2....
my target is £6, but I will top slice after FDA approval.

bought back in today - paid 16% more than I sold for - duh - but didn't want to miss the momentum...

decided to sell today for 20% profit after a chat with my broker who didn't like them in the portfolio due to them likely being stuck for circa 3 years. Still the price is holding up nicely so someone wants them....

exactly my opinion too rugs - 225 target for now...

who knows (or even cares). There a lot of hungry investors around who didn't get their allocation so let's assume a buy. I imagine a long queue of them, hoping for a dip....
ho ho

another key application, with P. the preferred technology - I also like the confident tone of "following FDA approval". Still not much move on the SP though - it needs to gap up above 100 to begin the real ascent...

exciting indeed - I wonder when the market will fully wake up to what is on the horizon - the SP should be up around 110 in anticipation. I'm interested to see how long the MMs can hold their nerve.

looking healthy today - I wonder if U of Basel has news forthcoming...?

thanks, that makes sense to me - strange how the simpler and therefore cheaper method trumps the sophisticated one....

well I'd be interested to hear your view on Cellsearch - I had a reply from AN about it over a year ago (he seemed quite relaxed)

there was word of them wanting to place shares at 10p prior to the big drop, so I'm guessing that's still their intention - and that would be the launch pad for 3 years of growth. No idea how we'll be able to sell the shares though!

decided to take a modest (£2.5K) punt on these today (paid a bit more than I wanted, ASK was at 1.5 but was made to pay 1.8) - the AI IP could be devastatingly good, and I'm content to sit for 5 years or so to let the company achieve its potential. I also like someone who puts two fingers up to AIM!

regarding those emails from BOD of Scancell, I did offer to send my correspondence to a trusted SCLP BB member, but he declined. If you want I'll send AN's last two replies to you, but I don't see the point as he will answer you himself. (that was not the case at Scancell - I had an existing academic correspondence with the board member in question). Of course folk doubt you when you pass on these messages, but I'm a long term holder of both companies, so I can't see what my motive would be!

yes, a key 'head to head' as Cellsearch is, as far as I know, the only company AN has admitted as a competitor (and their gear is way more expensive...). If Parsortix trumps them, we are in for quite a ride. If they win, then price point is still on Angle's side...